Small Molecule innovator CDMO Market (By Product: Small Molecule API, Small Molecule Drug Product; By Stage Type: Preclinical, Clinical, Commercial; By Customer Type: Pharmaceutical, Biotechnology; By Therapeutic Area: Cardiovascular Diseases, Oncology, Respiratory Disorders, Neurology, Metabolic Disorders, Infectious Diseases) - Global Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook 20222030

Chapter 1.  Introduction

1.1.  Research Objective

1.2.  Scope of the Study

1.3.  Definition

Chapter 2.  Research Methodology

2.1.  Research Approach

2.2.  Data Sources

2.3.  Assumptions & Limitations

Chapter 3.  Executive Summary

3.1.  Market Snapshot

Chapter 4.  Market Variables and Scope

4.1.  Introduction

4.2.  Market Classification and Scope

4.3.  Industry Value Chain Analysis

4.3.1.    Raw Material Procurement Analysis

4.3.2.    Sales and Customer Type Analysis

4.3.3.    Downstream Buyer Analysis

Chapter 5.  Market Dynamics Analysis and Trends

5.1.  Market Dynamics

5.1.1.    Market Drivers

5.1.2.    Market Restraints

5.1.3.    Market Opportunities

5.2.  Porter’s Five Forces Analysis

5.2.1.    Bargaining power of suppliers

5.2.2.    Bargaining power of buyers

5.2.3.    Threat of substitute

5.2.4.    Threat of new entrants

5.2.5.    Degree of competition

Chapter 6.  Competitive Landscape

6.1.1.    Company Market Share/Positioning Analysis

6.1.2.    Key Strategies Adopted by Players

6.1.3.    Vendor Landscape

6.1.3.1.        List of Suppliers

6.1.3.2.        List of Buyers

Chapter 7.  Global Small Molecule Innovator CDMO Market, By Product

7.1.  Small Molecule Innovator CDMO Market, by Product, 2021-2030

7.1.1.    Small Molecule API

7.1.1.1.        Market Revenue and Forecast (2019-2030)

7.1.2.    Small Molecule Drug Product

7.1.2.1.        Market Revenue and Forecast (2019-2030)

Chapter 8.  Global Small Molecule Innovator CDMO Market, By Stage Type

8.1.  Small Molecule Innovator CDMO Market, by Stage Type, 2021-2030

8.1.1.    Preclinical

8.1.1.1.        Market Revenue and Forecast (2019-2030)

8.1.2.    Clinical

8.1.2.1.        Market Revenue and Forecast (2019-2030)

8.1.3.    Commercial

8.1.3.1.        Market Revenue and Forecast (2019-2030)

Chapter 9.  Global Small Molecule Innovator CDMO Market, By Customer Type

9.1.  Small Molecule Innovator CDMO Market, by Customer Type, 2021-2030

9.1.1.    Pharmaceutical

9.1.1.1.        Market Revenue and Forecast (2019-2030)

9.1.2.    Biotechnology

9.1.2.1.        Market Revenue and Forecast (2019-2030)

Chapter 10.      Global Small Molecule Innovator CDMO Market, By Therapeutic Area

10.1.        Small Molecule Innovator CDMO Market, by Therapeutic Area, 2021-2030

10.1.1.  Cardiovascular Diseases

10.1.1.1.      Market Revenue and Forecast (2019-2030)

10.1.2.  Oncology

10.1.2.1.      Market Revenue and Forecast (2019-2030)

10.1.3.  Respiratory Disorders

10.1.3.1.      Market Revenue and Forecast (2019-2030)

10.1.4.  Neurology

10.1.4.1.      Market Revenue and Forecast (2019-2030)

10.1.5.  Metabolic Disorders

10.1.5.1.      Market Revenue and Forecast (2019-2030)

10.1.6.  Infectious Diseases

10.1.6.1.      Market Revenue and Forecast (2019-2030)

Chapter 11.      Global Small Molecule Innovator CDMO Market, Regional Estimates and Trend Forecast

11.1.        North America

11.1.1.  Market Revenue and Forecast, by Product (2019-2030)

11.1.2.  Market Revenue and Forecast, by Stage Type (2019-2030)

11.1.3.  Market Revenue and Forecast, by Customer Type (2019-2030)

11.1.4.  Market Revenue and Forecast, by Therapeutic Area (2019-2030)

11.1.5.  U.S.

11.1.5.1.      Market Revenue and Forecast, by Product (2019-2030)

11.1.5.2.      Market Revenue and Forecast, by Stage Type (2019-2030)

11.1.5.3.      Market Revenue and Forecast, by Customer Type (2019-2030)

11.1.5.4.      Market Revenue and Forecast, by Therapeutic Area (2019-2030)

11.1.6.  Rest of North America

11.1.6.1.      Market Revenue and Forecast, by Product (2019-2030)

11.1.6.2.      Market Revenue and Forecast, by Stage Type (2019-2030)

11.1.6.3.      Market Revenue and Forecast, by Customer Type (2019-2030)

11.1.6.4.      Market Revenue and Forecast, by Therapeutic Area (2019-2030)

11.2.        Europe

11.2.1.  Market Revenue and Forecast, by Product (2019-2030)

11.2.2.  Market Revenue and Forecast, by Stage Type (2019-2030)

11.2.3.  Market Revenue and Forecast, by Customer Type (2019-2030)

11.2.4.  Market Revenue and Forecast, by Therapeutic Area (2019-2030)

11.2.5.  UK

11.2.5.1.      Market Revenue and Forecast, by Product (2019-2030)

11.2.5.2.      Market Revenue and Forecast, by Stage Type (2019-2030)

11.2.5.3.      Market Revenue and Forecast, by Customer Type (2019-2030)

11.2.5.4.      Market Revenue and Forecast, by Therapeutic Area (2019-2030)

11.2.6.  Germany

11.2.6.1.      Market Revenue and Forecast, by Product (2019-2030)

11.2.6.2.      Market Revenue and Forecast, by Stage Type (2019-2030)

11.2.6.3.      Market Revenue and Forecast, by Customer Type (2019-2030)

11.2.6.4.      Market Revenue and Forecast, by Therapeutic Area (2019-2030)

11.2.7.  France

11.2.7.1.      Market Revenue and Forecast, by Product (2019-2030)

11.2.7.2.      Market Revenue and Forecast, by Stage Type (2019-2030)

11.2.7.3.      Market Revenue and Forecast, by Customer Type (2019-2030)

11.2.7.4.      Market Revenue and Forecast, by Therapeutic Area (2019-2030)

11.2.8.  Rest of Europe

11.2.8.1.      Market Revenue and Forecast, by Product (2019-2030)

11.2.8.2.      Market Revenue and Forecast, by Stage Type (2019-2030)

11.2.8.3.      Market Revenue and Forecast, by Customer Type (2019-2030)

11.2.8.4.      Market Revenue and Forecast, by Therapeutic Area (2019-2030)

11.3.        APAC

11.3.1.  Market Revenue and Forecast, by Product (2019-2030)

11.3.2.  Market Revenue and Forecast, by Stage Type (2019-2030)

11.3.3.  Market Revenue and Forecast, by Customer Type (2019-2030)

11.3.4.  Market Revenue and Forecast, by Therapeutic Area (2019-2030)

11.3.5.  India

11.3.5.1.      Market Revenue and Forecast, by Product (2019-2030)

11.3.5.2.      Market Revenue and Forecast, by Stage Type (2019-2030)

11.3.5.3.      Market Revenue and Forecast, by Customer Type (2019-2030)

11.3.5.4.      Market Revenue and Forecast, by Therapeutic Area (2019-2030)

11.3.6.  China

11.3.6.1.      Market Revenue and Forecast, by Product (2019-2030)

11.3.6.2.      Market Revenue and Forecast, by Stage Type (2019-2030)

11.3.6.3.      Market Revenue and Forecast, by Customer Type (2019-2030)

11.3.6.4.      Market Revenue and Forecast, by Therapeutic Area (2019-2030)

11.3.7.  Japan

11.3.7.1.      Market Revenue and Forecast, by Product (2019-2030)

11.3.7.2.      Market Revenue and Forecast, by Stage Type (2019-2030)

11.3.7.3.      Market Revenue and Forecast, by Customer Type (2019-2030)

11.3.7.4.      Market Revenue and Forecast, by Therapeutic Area (2019-2030)

11.3.8.  Rest of APAC

11.3.8.1.      Market Revenue and Forecast, by Product (2019-2030)

11.3.8.2.      Market Revenue and Forecast, by Stage Type (2019-2030)

11.3.8.3.      Market Revenue and Forecast, by Customer Type (2019-2030)

11.3.8.4.      Market Revenue and Forecast, by Therapeutic Area (2019-2030)

11.4.        MEA

11.4.1.  Market Revenue and Forecast, by Product (2019-2030)

11.4.2.  Market Revenue and Forecast, by Stage Type (2019-2030)

11.4.3.  Market Revenue and Forecast, by Customer Type (2019-2030)

11.4.4.  Market Revenue and Forecast, by Therapeutic Area (2019-2030)

11.4.5.  GCC

11.4.5.1.      Market Revenue and Forecast, by Product (2019-2030)

11.4.5.2.      Market Revenue and Forecast, by Stage Type (2019-2030)

11.4.5.3.      Market Revenue and Forecast, by Customer Type (2019-2030)

11.4.5.4.      Market Revenue and Forecast, by Therapeutic Area (2019-2030)

11.4.6.  North Africa

11.4.6.1.      Market Revenue and Forecast, by Product (2019-2030)

11.4.6.2.      Market Revenue and Forecast, by Stage Type (2019-2030)

11.4.6.3.      Market Revenue and Forecast, by Customer Type (2019-2030)

11.4.6.4.      Market Revenue and Forecast, by Therapeutic Area (2019-2030)

11.4.7.  South Africa

11.4.7.1.      Market Revenue and Forecast, by Product (2019-2030)

11.4.7.2.      Market Revenue and Forecast, by Stage Type (2019-2030)

11.4.7.3.      Market Revenue and Forecast, by Customer Type (2019-2030)

11.4.7.4.      Market Revenue and Forecast, by Therapeutic Area (2019-2030)

11.4.8.  Rest of MEA

11.4.8.1.      Market Revenue and Forecast, by Product (2019-2030)

11.4.8.2.      Market Revenue and Forecast, by Stage Type (2019-2030)

11.4.8.3.      Market Revenue and Forecast, by Customer Type (2019-2030)

11.4.8.4.      Market Revenue and Forecast, by Therapeutic Area (2019-2030)

11.5.        Latin America

11.5.1.  Market Revenue and Forecast, by Product (2019-2030)

11.5.2.  Market Revenue and Forecast, by Stage Type (2019-2030)

11.5.3.  Market Revenue and Forecast, by Customer Type (2019-2030)

11.5.4.  Market Revenue and Forecast, by Therapeutic Area (2019-2030)

11.5.5.  Brazil

11.5.5.1.      Market Revenue and Forecast, by Product (2019-2030)

11.5.5.2.      Market Revenue and Forecast, by Stage Type (2019-2030)

11.5.5.3.      Market Revenue and Forecast, by Customer Type (2019-2030)

11.5.5.4.      Market Revenue and Forecast, by Therapeutic Area (2019-2030)

11.5.6.  Rest of LATAM

11.5.6.1.      Market Revenue and Forecast, by Product (2019-2030)

11.5.6.2.      Market Revenue and Forecast, by Stage Type (2019-2030)

11.5.6.3.      Market Revenue and Forecast, by Customer Type (2019-2030)

11.5.6.4.      Market Revenue and Forecast, by Therapeutic Area (2019-2030)

Chapter 12.  Company Profiles

12.1.              Piramal Pharma Solutions

12.1.1.  Company Overview

12.1.2.  Product Offerings

12.1.3.  Financial Performance

12.1.4.  Recent Initiatives

12.2.              Corden Pharma

12.2.1.  Company Overview

12.2.2.  Product Offerings

12.2.3.  Financial Performance

12.2.4.  Recent Initiatives

12.3.              Wuxi AppTec

12.3.1.  Company Overview

12.3.2.  Product Offerings

12.3.3.  Financial Performance

12.3.4.  Recent Initiatives

12.4.              Cambrex Corporation

12.4.1.  Company Overview

12.4.2.  Product Offerings

12.4.3.  Financial Performance

12.4.4.  Recent Initiatives

12.5.              Recipharm AB

12.5.1.  Company Overview

12.5.2.  Product Offerings

12.5.3.  Financial Performance

12.5.4.  Recent Initiatives

12.6.              Thermo Fisher Pantheon

12.6.1.  Company Overview

12.6.2.  Product Offerings

12.6.3.  Financial Performance

12.6.4.  Recent Initiatives

12.7.              Lonza Group Ltd.

12.7.1.  Company Overview

12.7.2.  Product Offerings

12.7.3.  Financial Performance

12.7.4.  Recent Initiatives

12.8.              Catalent Inc.

12.8.1.  Company Overview

12.8.2.  Product Offerings

12.8.3.  Financial Performance

12.8.4.  Recent Initiatives

12.9.              Siegfried Holding AG

12.9.1.  Company Overview

12.9.2.  Product Offerings

12.9.3.  Financial Performance

12.9.4.  Recent Initiatives

12.10.           Boehringer Ingelheim

12.10.1.               Company Overview

12.10.2.               Product Offerings

12.10.3.               Financial Performance

12.10.4.               Recent Initiatives

Chapter 13.  Research Methodology

13.1.              Primary Research

13.2.              Secondary Research

13.3.              Assumptions

Chapter 14.  Appendix

14.1.              About Us

14.2.              Glossary of Terms